Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03858634 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT03858634 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 58 participants.
The verdict
NCT03858634, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
Participants with diseases characterized by chronic pruritus experiencing moderate to severe pruritus will be enrolled in this pilot Phase 2 study. The diseases characterized by chronic pruritus investigated in this pilot study currently include chronic idiopathic urticaria (CIU), chronic idiopathic pruritus (CIP), lichen planus (LP), lichen simplex chronicus (LSC) and plaque psoriasis (PPs).
Interventions
- DRUG Placebo
- DRUG KPL-716
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2019-05-29 |
| Est. Completion | 2020-06-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03858634
The ClinicalTrials.gov registry entry for NCT03858634 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03858634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03858634 about?
NCT03858634 is a clinical study titled "A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases". Participants with diseases characterized by chronic pruritus experiencing moderate to severe pruritus will be enrolled in this pilot Phase 2 study. The diseases characterized by chronic pruritus investigated in this pilot study currently include chronic idiopathic urticaria (CIU), chronic idiopathi...
What is the current status of trial NCT03858634?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2019-05-29. Estimated completion is 2020-06-08.
What interventions are being tested in trial NCT03858634?
The interventions under investigation include: Placebo (DRUG), KPL-716 (DRUG).
Who is sponsoring clinical trial NCT03858634?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.